Oil prices rise on talk of Russia sanctions; bouncing off recent lows
Stereotaxis (NYSE:STXS), Inc. (NYSE American:STXS), a leader in the field of robotic technologies for the treatment of cardiac arrhythmias with a market capitalization of $177 million and annual revenue of $27.5 million, announced the results of its Annual Meeting of Shareholders held on May 15, 2025. According to InvestingPro data, while the company maintains a strong gross margin of 53%, analysts expect continued challenges in achieving profitability this year. The company reported a 59% quorum with 63,792,419 shares represented at the meeting.
Two Class III directors were elected to serve until the 2028 Annual Meeting. Dr. Nathan Fischel received 43,049,508 votes for and 2,243,186 votes withheld, while Mr. Ross B. Levin received 42,319,392 votes for and 2,973,302 votes withheld. There were 18,499,725 broker non-votes for each nominee.
Additionally, shareholders ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year 2025. The proposal passed with 63,627,003 votes for, 126,608 against, and 38,808 abstentions.
The results ensure that Stereotaxis will continue its current strategic direction with the support of its shareholders. The elected directors are tasked with guiding the company through its next phase of innovation and growth in the medical device sector. With analyst price targets ranging from $4 to $5, investors seeking deeper insights can access the comprehensive Pro Research Report available on InvestingPro, which includes detailed analysis of the company’s growth prospects and financial health.
This announcement is based on a press release statement and reflects the official results of the Annual Meeting as filed with the SEC.
In other recent news, Stereotaxis Inc. reported its financial results for the first quarter of 2025, meeting Wall Street expectations with an EPS of -0.07 and surpassing revenue forecasts with $7.5 million, a 9% increase from the previous year. This revenue growth reflects the company’s strategic focus on expanding its product line, notably with the European approval of its MAGIC RF Ablation Catheter, which is now adopted by 20% of European hospitals. The company maintains a strong financial position with no debt and $10.7 million in cash and cash equivalents. Analysts from Piper Sandler and Lake Street Capital Markets noted the company’s progress and inquired about future adoption strategies for its products. Stereotaxis anticipates double-digit revenue growth throughout 2025, driven by its expanding product portfolio and strategic market initiatives. The company projects system revenue to fluctuate between $2-3 million quarterly, with recurring revenue expected to reach $7 million by Q4 2025. The positive reception of the MAGIC catheter in Europe is expected to contribute significantly to recurring revenue growth, with a projected $1 million per quarter by year-end.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.